Drug Profile
Research programme: cruzain inhibitors - Merck & Co
Alternative Names: Cruzain inhibitors research programme - ArQuleLatest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule
- Developer Merck & Co
- Class
- Mechanism of Action Cysteine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Trypanosomiasis
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 03 Jan 2001 Discontinued-Preclinical for Trypanosomiasis in USA (Unknown route)
- 16 Sep 1999 New profile